Morphological features and prognostic significance of ARID1A-deficient esophageal adenocarcinomas

Archives of Pathology and Laboratory Medicine

Volumn 141, Issue 7, 2017, Pages 970-977

  Drage, Michael G ^a   Tippayawong, Mingkhwan ^a   Agoston, Agoston T ^a   Zheng, Yifan ^a   Bueno, Raphael ^a   Hornick, Jason L ^a   Odze, Robert D ^a   Srivastava, Amitabh ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARID1A PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ADENOCARCINOMA; ADULT; AGED; BIOSYNTHESIS; DEFICIENCY; ESOPHAGUS TUMOR; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTL PROTEIN HOMOLOG 1; NUCLEAR PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 85021756176     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2016-0318-OA     Document Type: Conference Paper

References (38)

1. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010. World Health Organization Classification of Tumours; vol 3.
2. Farris AB III, Demicco EG, Le, LP, et al. Clinicopathologic and molecular profiles of microsatellite unstable Barrett esophagus-associated adenocarcinoma. Am J Surg Pathol. 2011; 35(5):647-655.
3. Falkenback D, Johansson J, Halvarsson B, Nilbert M. Defective mismatchrepair as a minor tumorigenic pathway in Barrett esophagus-associated adenocarcinoma. Cancer Genet Cytogenet. 2005; 157(1):82-86.
4. Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol. 2001; 14(5):397-403.
5. Mokrowiecka A, Wierzchniewska-Lawska A, Smolarz B, Romanowicz-Makowska H, Malecka-Panas E. p16 gene mutations in Barrett's esophagus in gastric metaplasia - intestinal metaplasia - dysplasia - adenocarcinoma sequence. Adv Med Sci. 2012; 57(1):71-76.
6. Menke V, Pot RG, Moons LM, et al. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. J Hum Genet. 2012; 57(1):26-32.
7. Marx AH, Zielinski M, Kowitz CM, et al. Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology. 2010; 57(3):418-426.
8. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 2007; 14(2):977-991.
9. Prins MJ, Ruurda JP, van Diest PJ, van Hillegersberg R, ten Kate FJ. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study. J Clin Pathol. 2014; 67(1):26-32.
10. Kulke MH, Thakore KS, Thomas G, et al. Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer. 2001; 91(8):1451-1457.
11. Muzeau F, Fléjou JF, Belghiti J, Thomas G, Hamelin R. Infrequent microsatellite instability in oesophageal cancers. Br J Cancer. 1997; 75(9):133-1339.
12. Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006; 106(3):483-493.
13. Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45(5):478-486.
14. Chong IY, Cunningham D, Barber LJ, et al. The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol. 2013; 231(3):301-310.
15. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PloS One. 2013; 8(1):e55119.
16. Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and swi/snf complexes during oncogenic transformation [published correction appears in Cancer Cell. 2011; 19(1):153]. Cancer Cell. 2010; 18(4): 316-328.
17. Zhang X, Sun Q, Shan M, et al. Promoter hypermethylation of ARID1A gene is responsible for its low MRNA expression in many invasive breast cancers. PloS One 2013; 8(1):e53931.
18. Shain AH, Giacomini CP, Matsukuma K, et al. Convergent structural alterations define switch/sucrose nonfermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A. 2012; 109(5):E252-E259.
19. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330(6001):228-231.
20. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometroid carcinoma. Am J Surg Pathol. 2011; 35(5):625-632.
21. Allo G, Bernardini MQ, Wu RC, et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol. 2014; 27(2):255-261.
22. Chou A, Toon CW, Clarkson A, et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014; 45(8):1697-1703.
23. Bosse T, Ter Haar NT, Seeber LM, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol. 2013; 26(11):1525-1535.
24. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
25. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003; 91(3):504-512.
26. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-1253.
27. Wu RC, Wang TL, Shih Ie M. The emerging roles of arid1a in tumor suppression. Cancer Biol Ther. 2014; 15(6):655-664.
28. Inada R, Sekine S, Taniguchi H, et al. ARID1A expression in gastric adenocarcinoma: Clinicopathological significance and correlation with DNA mismatch repair status. World J Gastroenterol. 2015; 21(7):2159-2168.
29. Abe H, Maeda D, Hino R, et al. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch. 2012; 461(4):367-377.
30. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012; 44(5):570-574.
31. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of arid1a in molecular subtypes of gastric cancer. Nat Genet. 2011; 43(12):1219-1223.
32. Luo B, Cheung HW, Subramanian A, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008; 105(51):2038-20385.
33. Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma [published correction appears in Nature. 2013; 500(7461):242]. Nature. 2013; 497(7447):67-73.
34. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268(5215):1336-1338.
35. Streppel MM, Lata S, DelaBastide M, et al. Next-generation sequencing of endoscopic biopsies identifies arid1a as a tumor-suppressor gene in Barrett's esophagus. Oncogene. 2014; 33(3);347-357.
36. Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an arid1a tumor suppressor role. Gene Chromosomes Cancer. 2007; 46(8):745-750.
37. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012; 25(4):615-624.
38. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012; 22(8):1310-1315.